Tim Maguire

CEO at VascuLogic

Greater New York City Area
Medical Devices

As a LinkedIn member, you'll join 300 million other professionals who are sharing connections, ideas, and opportunities.

  • See who you and Tim Maguire know in common
  • Get introduced to Tim Maguire
  • Contact Tim Maguire directly

View Tim's full profile

Tim Maguire's Overview

  • CEO at VascuLogic
  • CEO at Beau Ridge Pharmaceuticals
  • Director of Business Development at Rutgers CIVET
  • COO at Hurel Corporation
  • Senior Research Chemical Engineer at Merck

500+ connections


Tim Maguire's Summary

Dr. Maguire is a company founder, member of the Board of Directors, and currently President and Chief Executive Officer of VascuLogic LLC. He has led the company in these functions since its inception in 2010. Dr. Maguire transformed VascuLogic LLC from concept stage to a viable startup. Under Dr. Maguire’s leadership, the company is poised for Series A financing, and has built a solid portfolio in image-based medical devices and point of care diagnostics.

Prior to joining VascuLogic, Dr. Maguire has worked in the medical device and pharmaceutical industries for over 8 years in various roles of increased leadership and responsibility. These included positions within strategy, global manufacturing, business development, clinical R&D, and commercial teams. He has extensive experience in product launches and life-cycle management including MK-1572, Liptruzet, Victrelis, and Ibris. Additionally Dr. Maguire has raised over $5M in early stage funding, from both private and institutional investors.

Dr. Maguire is a doctoral graduate of the Department of Biomedical Engineering at Rutgers. His primary thesis focus was the design of scalable cellular therapeutic systems. In addition, at Rutgers, he conducted extensive work in the area of bioinformatics, and medical devices. In total Dr. Maguire has over 30 publications, 16 patent applications, and over 100 public presentations at a variety of high-impact conferences.

Specialties: Entrepreneurship, Operations, Growth Strategy, Business Development, Financial Modeling, Capital Structure Assessment, Medical Devices, Pharmaceuticals, Biotechnology

Tim Maguire's Experience

Privately Held; 1-10 employees; Medical Devices industry

May 2010Present (4 years 6 months) Piscataway, NJ 08854

•Spearheaded a medical device startup to develop multiple medical devices (5 Employees).
•Product 1: Autonomous venous access device. Projected recurring market: $2B+ (US).
•Product 2: Microfluidic point-of-need screening for ACD. Projected recurring market: $2B+ (US).
•Developed functional prototypes and validated through human clinical trials.
•Developed all financial models, business plans, and product development timelines.


Beau Ridge Pharmaceuticals

January 2013Present (1 year 10 months) Greater New York City Area

Director of Business Development

Rutgers CIVET

Educational Institution; 10,001+ employees; Higher Education industry

May 2010Present (4 years 6 months) Piscataway, NJ 08854

•Lead team to restructure the medical device commercialization and CRO work at Rutgers University.
•Established industrial research contracts with large pharmaceutical and cosmetic companies ($2M+).
•Planned and managed client facing work with 100% timely completion of major milestones.
•Authored business plans and financial models for 20+ Rutgers-Based startups.

Associate Research Professor

Rutgers University

Educational Institution; 10,001+ employees; Higher Education industry

January 2010Present (4 years 10 months) Piscataway NJ

•Project 1: Development of physiologically relevant microfluidics systems for toxicity assessment.
•Project 2: Development of metabolic conditioning and cell therapies for the treatment of liver failure.
•Project 3: Development of Stem cell based therapies for the treatment of TBI, and spinal cord injury.

Adjunct Faculty

Harvard Medical School

Educational Institution; 10,001+ employees; Higher Education industry

May 2010Present (4 years 6 months) Greater Boston Area

•Project 1: MEMs based diagnostics.
•Project 2: Bioartificial liver development.
•Project 3: Decellularized liver scaffolds as tissue engineering therapies.


Hurel Corporation

October 2008May 2010 (1 year 8 months) Kennilworth NJ

Senior Research Chemical Engineer


Public Company; 10,001+ employees; MRK; Pharmaceuticals industry

November 2006October 2008 (2 years) West Point, PA

•Developed combined project complexity and resource allocation model, focused on reducing lead-time, reducing scale-up cost, integrating clinical and commercial functions throughout the development process, setting expectations for senior management reviews, and aligning strategy with execution.
•Led a cross-divisional team to develop new computational tools to reduce intermediate scale-up and validation steps for compounds.

Product Development
•Led early formulation and process development for a variety of solid dosage and liquid filled capsule formulations for multiple franchises including HCV, Oncology, and the Merck-Schering Plough JV.
•Implemented FDA Quality by Design standards for five compounds, establishing the process for future solid dosage formulation and transition to scale-up.
•Extensive experience in solid dosage formulation, spray drying amorphous compounds, and hot-melt extrusion.

Tim Maguire's Certifications

  • 2015 Level I CFA Candidate

    • CFA Institute

Tim Maguire's Education

Rutgers, The State University of New Jersey-New Brunswick

PhD, BioMedical Engineering


Activities and Societies: President of the Biomedical Engineering Student Society (BESS)

Rutgers University-New Brunswick

BS, Chemical Engineering


Activities and Societies: Chemical Engineering Honor Society

Tim Maguire's Patents

  • An automated vessel puncture device using three-dimensional(3d) near infrared (nir) imaging and a robotically driven needle

    • United States Patent Application US2009/062550
    • Filed October 29, 2009
    Inventors: Tim Maguire

    The present invention is directed to an automated vessel puncture device, methods of mapping three-dimensional views of subcutaneous vessels and methods for providing simultaneous real-time diagnostic assay.

  • Alginate poly-l-lysine encapsulation as a technology for controlled differentiation of embryonic stem cells

    • United States Patent US2006/017968
    • Issued May 9, 2006
    Inventors: Tim Maguire

    Alginate polyelectrolyte encapsulation is used for the controlled differentiation of embryonic stem cells. An isolated cell population is provided. The cell population includes a single cell suspension of ES cells encapsulated within an alginate polyelectrolyte microenvironment. The encapsulated ES cells are capable of differentiating within said microenvironment into hepatocyte lineage cells in the absence of embryoid body intermediates or growth factor supplementation.

  • High throughput sensitization detection devices and methods

    • United States Patent US2012/050375
    • Issued August 10, 2012
    Inventors: Tim Maguire

    This invention discloses devices and methods for high throughput skin sensitization detection. The devices comprise a microfibricated chamber comprising a region having one or more input channels and an outlet, and a face suitable for mounting a skin tissue and in fluidic communication with the region. The devices can be used in the methods for determining a prognosis of sensitization in an animal subject and identifying compounds that do not cause sensitization and thus are suitable for preparing cosmetic compositions.

Tim Maguire's Publications

  • Physiologically Based Pharmacokinetic Models: Integration of In Silico Approaches with Micro Cell Culture Analogues.

    • Current Drug Metabolism
    • May 8, 2012

    There is a large emphasis within the pharmaceutical industry to provide tools that will allow early research and development groups to better predict dose ranges for and metabolic responses of candidate molecules in a high throughput manner, prior to entering clinical trials. These tools incorporate approaches ranging from PBPK, QSAR, and molecular dynamics simulations in the in silico realm, to micro cell culture analogue (CCAs)s in the in vitro realm. This paper will serve to review these areas of high throughput predictive research, and highlight hurdles and potential solutions. In particular we will focus on CCAs, as their incorporation with PBPK modeling has the potential to replace animal testing, with a more predictive assay that can combine multiple organ analogs on one microfluidic platform in physiologically correct volume ratios. While several advantages arise from the current embodiments of CCAS in a microfluidic format that can be exploited for realistic simulations of drug absorption, metabolism and action, we explore some of the concerns with these systems, and provide a potential path forward to realizing animal-free solutions. Furthermore we envision that, together with theoretical modeling, CCAs may produce reliable predictions of the efficacy of newly developed drugs.

  • Tissue engineering and regenerative medicine: history, progress, and challenges.

    • Annual Review of Chemical and Biochemical Engineering
    • 2011

    The past three decades have seen the emergence of an endeavor called tissue engineering and regenerative medicine in which scientists, engineers, and physicians apply tools from a variety of fields to construct biological substitutes that can mimic tissues for diagnostic and research purposes and can replace (or help regenerate) diseased and injured tissues. A significant portion of this effort has been translated to actual therapies, especially in the areas of skin replacement and, to a lesser extent, cartilage repair. A good amount of thoughtful work has also yielded prototypes of other tissue substitutes such as nerve conduits, blood vessels, liver, and even heart. Forward movement to clinical product, however, has been slow. Another offshoot of these efforts has been the incorporation of some new exciting technologies (e.g., microfabrication, 3D printing) that may enable future breakthroughs. In this review we highlight the modest beginnings of the field and then describe three application examples that are in various stages of development, ranging from relatively mature (skin) to ongoing proof-of-concept (cartilage) to early stage (liver). We then discuss some of the major issues that limit the development of complex tissues, some of which are fundamentals-based, whereas others stem from the needs of the end users.

  • Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates.

    • Current Drug Metabolism
    • 2009

    One of the fundamental challenges facing the development of new chemical entities within the pharmaceutical industry is the extrapolation of key in vivo parameters from in vitro cell culture assays and animal studies. Development of microscale devices and screening assays incorporating primary human cells can potentially provide better, faster and more efficient prediction of in vivo toxicity and clinical drug performance. With this goal in mind, large strides have been made in the area of microfluidics to provide in vitro surrogates that are designed to mimic the physiological architecture and dynamics. More recent advancements have been made in the development of in vitro analogues to physiologically-based pharmacokinetic (PBPK) models - a mathematical model that represents the body as interconnected compartments specific for a particular organ. In this review we highlight recent advancements in human hepatocyte microscale culture, and describe the next generation of integrated devices, whose potential allows for the high throughput assessment of drug metabolism, distribution and pharmacokinetics.

  • A microfluidic hepatic coculture platform for cell-based drug metabolism studies.

    • Biochemical Pharmacology
    • April 1, 2010

    Within the global pharmaceutical and biotech industries, there is significant interest in identifying in vitro screening systems that are more human-relevant-i.e., that offer greater utility in predicting subcellular and cellular physiological responses in humans in vivo-and that thereby allow investigators to reduce the incidence of costly late-stage failures during pharmaceutical clinical trials, as well as to reduce the use of animals in drug testing. Currently incumbent in vitro screening methods, such as culturing human hepatocytes in suspension, while useful, are limited by a lack of long term cellular function. In order to address this limitation, we have established an integrated, microfluidic, in vitro platform that combines the patented HmuREL((R)) microdevice with a hepatic coculture system. In the present report, we use this platform to study clearance and metabolite generation of a battery of molecular entities. The results show that the flow-based coculture system is capable of clearing, with improved resolution and predictive value, compounds with high, medium, and low clearance values. In addition, when coculture is coupled with flow, higher metabolite production rates are obtained than in static systems.

  • Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human.

    • Biochem Pharmacol.
    • September 2009
  • Liver Defatting: An Alternative Approach to Enable Steatotic Liver Transplantation

    • American Journal of Transplantation
    • October 11, 2012

    Macrovesicular steatosis in greater than 30% of hepatocytes is a significant risk factor for primary graft nonfunction due to increased sensitivity to ischemia reperfusion (I/R) injury. The growing prevalence of hepatic steatosis due to the obesity epidemic, in conjunction with an aging population, may negatively impact the availability of suitable deceased liver donors. Some have suggested that metabolic interventions could decrease the fat content of liver grafts prior to transplantation. This concept has been successfully tested through nutritional supplementation in a few living donors. Utilization of deceased donor livers, however, requires defatting of explanted organs. Animal studies suggest that this can be accomplished by ex vivo warm perfusion in a time scale of a few hours. We estimate that this approach could significantly boost the size of the donor pool by increasing the utilization of steatotic livers. Here we review current knowledge on the mechanisms whereby excessive lipid storage and macrosteatosis exacerbate hepatic I/R injury, and possible approaches to address this problem, including ex vivo perfusion methods as well as metabolically induced defatting. We also discuss the challenges ahead that need to be addressed for clinical implementation.

  • Elevated Sensitivity of Macrosteatotic Hepatocytes to Hypoxia-Reoxygenation Stress Is Reversed by a Novel Defatting Protocol

    • Liver Transplantation (accepted for publication)

    Macrosteatotic livers exhibit elevated intrahepatic triglyceride (TG) content in the form of large lipid droplets (LDs), reduced ATP, and elevated reactive oxygen species (ROS), contributing to their elevated sensitivity to ischemia-reperfusion injury during transplantation. Decreasing macrosteatosis in living donors through dieting has been shown to improve transplantation outcome.
    Accomplishing the same feat in deceased donor grafts would require ex-vivo exposure to potent defatting agents.

    Herein, we used a rat hepatocyte culture system exhibiting macrosteatotic LD morphology, elevated TG levels, and elevated sensitivity to hypoxia and reoxygenation (H/R), to test for such agents and ameliorate H/R sensitivity. Macrosteatotic hepatocyte preconditioning for 48h with a
    defatting cocktail, previously developed to promote TG catabolism, reduced the number of macrosteatotic LDs and intracellular TG levels by 82% and 27%, respectively, but did not ameliorate sensitivity to H/R.
    L-carnitine supplementation to this cocktail, together with hyperoxic exposure, yielded a similar reduction in macrosteatotic LD numbers, and to a 57% reduction in intrahepatic TG storage, likely by increasing the supply of acetyl-CoA to mitochondria, as indicated by a 70% increase in ketone body secretion.
    Furthermore, this treatment reduced ROS levels by 32%, increased ATP levels by 27%, nearing ATP levels of lean controls, and completely abolished H/R sensitivity as indicated by ~85% viability post H/R and return of cytosolic lactate dehydrogenase release down to levels seen in lean controls.
    Cultures maintained for 48h post H/R were ~83% viable and exhibited superior urea secretion and bile canalicular transport compared to untreated macrosteatotic cultures. These findings show that the elevated sensitivity of macrosteatotic hepatocytes to H/R can be overcome by defatting agents, suggesting a possible route for the recovery of discarded macrosteatotic grafts.

Tim Maguire's Skills & Expertise

  1. Biotechnology
  2. Biomedical Engineering
  3. Medical Devices
  4. R&D
  5. Cell Biology
  6. Tissue Engineering
  7. Start-ups
  8. Commercialization
  9. Business Strategy
  10. Pharmaceutical Industry
  11. Drug Delivery
  12. Bioinformatics
  13. Lifesciences
  14. Entrepreneurship
  15. Strategy
  16. FDA
  17. Clinical Research
  18. Operations Management
  19. Biomaterials
  20. Cell Culture
  21. Project Management
  22. Mobile Applications
  23. Clinical Development
  24. Stem Cells
  25. Biochemistry
  26. Neuroscience
  27. Clinical Trials
  28. Technology Transfer
  29. Financial Analysis
  30. Validation
  31. Molecular Biology
  32. Product Development
  33. Drug Discovery
  34. Biopharmaceuticals
  35. PCR
  36. Assay Development
  37. Business Development
  38. Drug Development
  39. Pharmacology
  40. Analytics
  41. Nanotechnology
  42. Financial Modeling
  43. Immunology
  44. jQuery
  45. Python
  46. SPSS

View All (46) Skills View Fewer Skills

Contact Tim for:

  • career opportunities
  • consulting offers
  • new ventures
  • job inquiries
  • expertise requests
  • business deals
  • reference requests
  • getting back in touch

View Tim Maguire’s full profile to...

  • See who you and Tim Maguire know in common
  • Get introduced to Tim Maguire
  • Contact Tim Maguire directly

View Tim's full profile

Not the Tim Maguire you were looking for? View more »

Viewers of this profile also viewed...